SCHEMBL3187690

SCHEMBL3187690

Cc1ccc(O)c(C(O)=S)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 1/20 0.63
TRPA1 O75762 2/20 0.52
TP53 P04637 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
ALOX15 P16050 2/20 0.46
HSD17B10 Q99714 2/20 0.46
ALDH1A1 P00352 1/20 0.46
MCL1 Q07820 1/20 0.46
LMNA P02545 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
MAPT P10636 2/20 0.45
HPGD P15428 2/20 0.45
GAA P10253 1/20 0.45
ALOX12 P18054 1/20 0.45
RAB9A P51151 3/20 0.41
POLB P06746 1/20 0.41
KDM4E B2RXH2 1/20 0.41
FTO Q9C0B1 1/20 0.40
AMY1A P0DUB6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8433610 0.82 TRPA1 (0.52) CSNK2A1TRPA1TP53TDP1ALOX15
SCHEMBL11044723 0.80 CSNK2A1 (0.55) CSNK2A1TRPA1TP53TDP1ALOX15
SCHEMBL29740060 0.77 CSNK2A1 (1.00) CSNK2A1TRPA1TDP1ALOX15HSD17B10
SCHEMBL127149 0.77 CSNK2A1 (1.00) CSNK2A1TRPA1TDP1ALOX15HSD17B10
SCHEMBL10702551 0.77 CSNK2A1 (0.52) CSNK2A1TRPA1TP53TDP1ALOX15
SCHEMBL10373446 0.77 CSNK2A1 (0.52) CSNK2A1TRPA1TP53TDP1ALOX15
SCHEMBL6715407 0.76 CA12 (0.60) ALOX15HSD17B10ALDH1A1LMNAMEN1
Ammonia Solution, Strong SCHEMBL25338596 0.76 CSNK2A1 (0.96) CSNK2A1TRPA1TDP1ALOX15HSD17B10
SCHEMBL18741297 0.76 CSNK2A1 (0.96) CSNK2A1TDP1ALOX15HSD17B10ALDH1A1
SCHEMBL18741295 0.76 CSNK2A1 (0.96) CSNK2A1TRPA1TDP1ALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109899-A1 BENZOFURAN COMPOUNDS AS STING AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2024-04-04 US disclosed
CN-1872846-B Method of preparing 2-benzothiazepines derivative UBE INDUSTRIES 2010-06-16 CN disclosed
US-7671195-B2 Process for preparing dibenzothiazepine compounds ASTRAZENECA UK LIMITED (GB) 2010-03-02 US disclosed
CN-100577653-C Process for preparing dibenzothiazepine  derivatives UBE INDUSTRIES 2010-01-06 CN disclosed
US-7576241-B2 Derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them IPSEN PHARMA S.A.S. (FR) 2009-08-18 US disclosed
CN-101389615-A Process for preparing dibenzothiazepine  compounds ASTRAZENECA UK LTD UBE IND (GB) 2009-03-18 CN disclosed
US-7473779-B2 Derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-01-06 US disclosed
EP-1996568-A2 PROCESS FOR PREPARING DIBENZOTHIAZEPINE COMPOUNDS AstraZeneca UK Limited (GB) 2008-12-03 EP disclosed
US-7314930-B2 Process for preparing dibenzothiazepine derivatives UBE INDUSTRIES, LTD. (JP) 2008-01-01 US disclosed
WO-2007102352-A2 PROCESS FOR PREPARING DIBENZOTHIAZEPINE COMPOUNDS ASTRAZENECA UK LIMITED (GB) 2007-09-13 WO disclosed
CN-85109587-A Have the new benzothiophene kind of antiallergic activity and the preparation method of benzofuran compounds 1986-12-17 CN disclosed
EP-0187487-A1 Benzothiophenes and benzofurans having antiallergic activity WARNER-LAMBERT COMPANY (US) 1986-07-16 EP disclosed
EP-0005607-B1 XANTHONE AND THIOXANTHONE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM KEFALAS A/S (DK) 1983-10-26 EP disclosed
EP-0026000-B1 SPIRO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Takeda Chemical Industries, Ltd. (JP) 1983-05-11 EP disclosed
US-4362740-A ANTICOAGULANTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1982-12-07 US disclosed
US-4285956-A NEUROLEPTIC AND ANTICHOLENERGIC AGENTS; PSYCHOLOGICAL DISORDERS INCLUDING SCHIZOPHRENIA; ANTIEMETIC AGENTS KEFALAS A/S (DK) 1981-08-25 US disclosed
US-4275209-A NEUROLEPTIC AND ANTIEMETIC ACTIVITY FOR TREATMENT OF PSYCHOLOGICAL DISORDERS KEFALAS A/S (DK) 1981-06-23 US disclosed
EP-0026000-A1 Spiro compounds, process for their preparation and pharmaceutical compositions containing them Takeda Chemical Industries, Ltd. (JP) 1981-04-01 EP disclosed
EP-0005607-A1 Xanthone and thioxanthone derivatives, their preparation and pharmaceutical compositions containing them KEFALAS A/S (DK) 1979-11-28 EP disclosed
US-4006243-A FUNGICIDE, BACTERICIDE, YEAST SCHERING AKTIENGESELLSCHAFT (DT) 1977-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109899-A1 BENZOFURAN COMPOUNDS AS STING AGONISTS STING1, MAVS, IRF3 CSNK2A1 2453/4885TRPA1 42/4885TP53 1466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.